|
|
|
| home > pmps > autumn 2003 > new orbital welding documentation method improves accuracy for inspections and leads to lower cost per weld |
|
|
 PUBLICATIONS |
Pharmaceutical Manufacturing and Packing Sourcer
|
Orbital tube welding is the recommended method of fabrication for bioprocessing equipment. It has not changed significantly since the 1960s when it was introduced into the aerospace industry. Operators still use the gas tungsten arc welding (GTAW) process and orbit or rotate an electrode around a fixtured weld joint with a predetermined set of weld parameters programmed into the power supply (1). While the orbital welding process itself has remained largely unchanged, advancements in welding system technology have greatly improved weld documentation. For example, today's orbital welding equipment utilises microprocessor technology that provides interface capabilities, enabling data to be transferred to other computers for analysing and customising reports that document quality, cost of welds and other critical information. These types of advancements address increasing requirements for bioprocessing systems.
Weld documentation provides full traceability for all materials and procedures used for construction and maintenance of bioprocessing systems. Such documentation must provide the necessary verification that each weld meets the weld acceptance criteria as defined by the weld specification. In the event of a problem with a system, such as contamination, the documentation provides a means to go back and review each welded connection as part of the effort to track down and find the source.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
News and Press Releases |
 |
Registration Opens for Inaugural HPAPI USA Conference in October
The HPAPI global market is growing at an ever-increasing rate of CAGR at 8.6% that is projected to reach USD $31.56 Billion by 2025, with a significant segment market of HPAPI being oncology ADC which is at a CARG of a staggering 20%. The continual elevation of HPAPI potencies along with toxicity will further drive the needs for more cutting-edge containment solutions and best practices guidelines to ensure workers safety.
More info >> |
|
 |
White Papers |
 |
|
The Power of Execution in Clinical Research
Medpace
Medpace, long known for its excellence in conducting Phase I-IV studies
on a global platform, is particularly noted for its therapeutic
excellence. When that expertise is combined with operational precision,
the results are nothing short of stellar. The Medpace full-service
outsourcing approach – combined with therapeutic expertise, regulatory
know how, and global presence – delivers clinical studies with an
industry recognized track record.
More info >> |
|
 |
Industry Events |
 |
CPhI & P-MEC China
18-20 June 2019, SNIEC, Shanghai, China
CPhI & P-MEC China 2019 is your gateway to successfully grow your business at the 2nd largest pharma market in the world. Whether you are looking for sourcing new business or getting the latest market insight, this is your one-stop shop pharmaceutical platform in Asia.
More info >> |
|
|
